Streetbeat News

ARTV

Artiva Biotherapeutics Inc

Industry

Research and Development in Biotechnology (except Nanobiotechnology)

Open

13.00

Mkt cap

323M

Volume

49K

High

13.76

P/E Ratio

-14.30

52-wk high

17.31

Low

12.26

Div yield

N/A

52-wk low

9.68

Needham analyst Gil Blum has reiterated a Buy rating on Artiva Biotherapeutics (NASDAQ:ARTV) and maintained a price target of $23.

Portfolio Pulse from Benzinga Newsdesk

August 30, 2024 | 3:58 pm

Artiva Biotherapeutics reported a significant increase in quarterly losses, with Q2 EPS at $(22.00), a 56.14% decrease from $(14.09) in the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 29, 2024 | 8:14 pm

Artiva Biotherapeutics (NASDAQ:ARTV) recently priced its IPO at $12.00 per share, raising approximately $167 million. The company focuses on developing cell therapies for autoimmune diseases and cancers, with its lead program, AlloNK, currently in clinical trials. Needham and Wedbush have initiated coverage with bullish ratings and price targets of $23 and $18, respectively. Initial clinical results for AlloNK in lupus are expected in the first half of 2025.

Portfolio Pulse from Vandana Singh

August 13, 2024 | 6:14 pm

Needham analyst Gil Blum has initiated coverage on Artiva Biotherapeutics (NASDAQ:ARTV) with a Buy rating and a price target of $23.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 1:42 pm

Wedbush analyst David Nierengarten has initiated coverage on Artiva Biotherapeutics (NASDAQ:ARTV) with an Outperform rating and a price target of $18.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 12:45 pm

Cantor Fitzgerald has initiated coverage on Artiva Biotherapeutics (NASDAQ:ARTV) with an Overweight rating and a price target of $23.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 11:26 am

TD Cowen has initiated coverage on Artiva Biotherapeutics (NASDAQ:ARTV) with a Buy rating, as announced by analyst Tyler Van Buren.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 11:23 am

Jefferies analyst Kelly Shi has initiated coverage on Artiva Biotherapeutics (NASDAQ:ARTV) with a Buy rating and set a price target of $21.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 10:41 am

Trading halt status for ARTV was updated at 10:10:00 AM ET. The IPO security has been released for quotation.

Portfolio Pulse from Benzinga Newsdesk

July 19, 2024 | 2:10 pm

Artiva Biotherapeutics has priced its upsized $167 million initial public offering (IPO) of 13.92 million common shares at $12 per share. The shares will begin trading on the Nasdaq Global Market under the symbol 'ARTV' on July 19, 2024, with the offering expected to close on July 22, 2024, pending customary closing conditions.

Portfolio Pulse from Benzinga Newsdesk

July 19, 2024 | 6:27 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.